One trial is a single-center, single arm, open-label pilot study to evaluate the safety and feasibility of CAR-NK cell treatment in subjects with metastatic solid tumors using autologous or allogeneic NK cells transfected by mRNA electroporation against NKG2D-ligand expressing cancer cells (NCT03415100). This evidence concerns the gene KLRK1 and cancer.